Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH004 as Monotherapy and in Combination with Toripalimab in Advanced Solid Tumors and Relapsed/Refractory NHL
NCT05040932Phase 1Completed
- Sponsor
- Eucure Biopharma
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YH004 in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Eucure Biopharma. Primary endpoints: Treatment-emergent adverse events up to 24 months and Maximum tolerated dose and/or recommended Phase II dose up to 24 months. Started Dec 2021; status: completed.
02
Drugs
YH004
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05040932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040932.